Gapping down
In reaction to disappointing earnings/guidance:
- PACB -17.5%, HOLX -10.3%, SPOT -9.4%, EPC -7.7%, IO -7.4%, CRUS -7.4%, FIT -6.9%, CAH -6.5%, WPX -6%, SQ -5.8%, AIG -5.8%, FEYE -5.7%, SNN -5.7%, NXPI -5.5%, WIN -5.5%, HOS -5%, TSLA -4.8%, FND -4.6%, TUSK -4.5%, LGCY -3.8%, CERN -3.6%, HABT -3%, AI -2.5%, TYL -2.3%, DDD -2.3%, (also Apergy will replace 3D Systems in the S&P MidCap 400, who will replace Impax Laboratories in the S&P SmallCap 600), BERY -2.3%, CLR -1.8%, PAH -1.7%, AFG -1.6%, ESRX -1.5%, SBGL -1.4%, XPO -1.2%, AWK -1.1%, ZNGA -1.1%, HZN -1.1%, DWDP -1%
Other news:
- AKAO -25.7% (FDA 'in favor of plazomicin for complicated' UTI )
- MEDP -8.2% (Medpace commences 3 mln common stock offering by selling shareholder Cinvven Capital)
- QURE -4.5% (prices offering of 4.5 mln ordinary shares at $28.50 per share)
- KPTI -3.8% (prices offering of 9,152,543 shares of its common stock at $14.75 per share)
- SIEN -2.2% (prices 7,407,408 shares (upsized from $75 mln) of its common stock at a public offering price of $13.50 per share)
- PANW -0.9% (following FEYE results)
Analyst comments:
- CAT -1.2% (downgraded to Neutral from Buy at BofA/Merrill)
- MBUU -1.7% (downgraded to Market Perform from Outperform at Wells Fargo)
- ESPR -0.5% (downgraded to Underweight from Neutral at JP Morgan)